Search

Author/Creator Wakamatsu, Sho

1. Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol. (15th May 2021)

Authors:
Jojima, Teruo; Sakurai, Shintaro; Wakamatsu, Sho; Iijima, Toshie; Saito, Masahiro; Tomaru, Takuya; Kogai, Takahiko; Usui, Isao; Aso, Yoshimasa
Journal:
International journal of cardiology
Issue:
Volume 331(2021)
Page Start:
243
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial. (24th May 2017)

Authors:
Kato, Kanako; Suzuki, Kunihiro; Aoki, Chie; Sagara, Masaaki; Niitani, Takafumi; Wakamatsu, Sho; Yanagi, Kazunori; Aso, Yoshimasa
Journal:
Expert opinion on pharmacotherapy
Issue:
Volume 18:Number 8(2017)
Page Start:
743
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗